...
首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Suprachoroidal electrotransfer: A nonviral gene delivery method to transfect the choroid and the retina without detaching the retina
【24h】

Suprachoroidal electrotransfer: A nonviral gene delivery method to transfect the choroid and the retina without detaching the retina

机译:脉络膜上电转移:一种非病毒基因传递方法,可在不脱离视网膜的情况下转染脉络膜和视网膜

获取原文
获取原文并翻译 | 示例
           

摘要

Photoreceptors and retinal pigment epithelial cells (RPE) targeting remains challenging in ocular gene therapy. Viral gene transfer, the only method having reached clinical evaluation, still raises safety concerns when administered via subretinal injections. We have developed a novel transfection method in the adult rat, called suprachoroidal electrotransfer (ET), combining the administration of nonviral plasmid DNA into the suprachoroidal space with the application of an electrical field. Optimization of injection, electrical parameters and external electrodes geometry using a reporter plasmid, resulted in a large area of transfected tissues. Not only choroidal cells but also RPE, and potentially photoreceptors, were efficiently transduced for at least a month when using a cytomegalovirus (CMV) promoter. No ocular complications were recorded by angiographic, electroretinographic, and histological analyses, demonstrating that under selected conditions the procedure is devoid of side effects on the retina or the vasculature integrity. Moreover, a significant inhibition of laser induced-choroidal neovascularization (CNV) was achieved 15 days after transfection of a soluble vascular endothelial growth factor receptor-1 (sFlt-1)-encoding plasmid. This is the first nonviral gene transfer technique that is efficient for RPE targeting without inducing retinal detachment. This novel minimally invasive nonviral gene therapy method may open new prospects for human retinal therapies.
机译:在眼基因治疗中,靶向光感受器和视网膜色素上皮细胞(RPE)仍然具有挑战性。通过视网膜下注射给药时,病毒基因转移是达到临床评估的唯一方法,仍然引起安全隐患。我们已经开发了一种在成年大鼠中的新型转染方法,称为脉络膜上电转移(ET),该方法将非病毒质粒DNA的给药与电场结合起来。使用报告质粒优化注射,电参数和外部电极的几何形状,可导致大面积转染组织。当使用巨细胞病毒(CMV)启动子时,不仅脉络膜细胞而且RPE和潜在的感光细胞都被有效地转导了至少一个月。通过血管造影,视网膜电图和组织学分析未记录到任何眼部并发症,这表明在选定的条件下,该手术对视网膜或脉管系统的完整性没有副作用。此外,转染可溶性血管内皮生长因子受体1(sFlt-1)编码质粒15天后,实现了激光诱导的脉络膜新生血管形成(CNV)的显着抑制。这是第一种有效的RPE靶向而不引起视网膜脱离的非病毒基因转移技术。这种新颖的微创非病毒基因治疗方法可能为人类视网膜治疗打开新的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号